🚀 VC round data is live in beta, check it out!
Krystal Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Krystal Biotech and similar public comparables like Kyowa Kirin, Halozyme Therapeutics, ImmunityBio, Cytokinetics and more.
Krystal Biotech Overview
About Krystal Biotech
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Founded
2017
HQ
Employees
295
Website
Sectors
Financials (LTM)
EV
$7B
Krystal Biotech Financials
Krystal Biotech reported last 12-month revenue of $428M and EBITDA of $182M.
In the same LTM period, Krystal Biotech generated $402M in gross profit, $182M in EBITDA, and $208M in net income.
Revenue (LTM)
Krystal Biotech P&L
In the most recent fiscal year, Krystal Biotech reported revenue of $389M and EBITDA of $168M.
Krystal Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $428M | XXX | $389M | XXX | XXX | XXX |
| Gross Profit | $402M | XXX | $366M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | $182M | XXX | $168M | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 43% | XXX | XXX | XXX |
| EBIT Margin | 43% | XXX | 41% | XXX | XXX | XXX |
| Net Profit | $208M | XXX | $205M | XXX | XXX | XXX |
| Net Margin | 49% | XXX | 53% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Krystal Biotech Stock Performance
Krystal Biotech has current market cap of $8B, and enterprise value of $7B.
Market Cap Evolution
Krystal Biotech's stock price is $274.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $8B | 3.8% | XXX | XXX | XXX | $6.96 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKrystal Biotech Valuation Multiples
Krystal Biotech trades at 16.9x EV/Revenue multiple, and 40.0x EV/EBITDA.
EV / Revenue (LTM)
Krystal Biotech Financial Valuation Multiples
As of April 19, 2026, Krystal Biotech has market cap of $8B and EV of $7B.
Equity research analysts estimate Krystal Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Krystal Biotech has a P/E ratio of 38.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV/Revenue | 16.9x | XXX | 18.6x | XXX | XXX | XXX |
| EV/EBITDA | 40.0x | XXX | 43.2x | XXX | XXX | XXX |
| EV/EBIT | 39.8x | XXX | 44.9x | XXX | XXX | XXX |
| EV/Gross Profit | 18.0x | XXX | 19.8x | XXX | XXX | XXX |
| P/E | 38.7x | XXX | 39.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 38.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Krystal Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Krystal Biotech Margins & Growth Rates
Krystal Biotech's revenue in the last 12 month grew by 31%.
Krystal Biotech's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.7M for the same period.
Krystal Biotech's rule of 40 is 77% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Krystal Biotech's rule of X is 127% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Krystal Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 43% | XXX | XXX | XXX |
| EBITDA Growth | 35% | XXX | 33% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 77% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 127% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 36% | XXX | 37% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Krystal Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Krystal Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Kyowa Kirin | XXX | XXX | XXX | XXX | XXX | XXX |
| Halozyme Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| ImmunityBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Cytokinetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kelun | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Krystal Biotech M&A Activity
Krystal Biotech acquired XXX companies to date.
Last acquisition by Krystal Biotech was on XXXXXXXX, XXXXX. Krystal Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Krystal Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKrystal Biotech Investment Activity
Krystal Biotech invested in XXX companies to date.
Krystal Biotech made its latest investment on XXXXXXXX, XXXXX. Krystal Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Krystal Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Krystal Biotech
| When was Krystal Biotech founded? | Krystal Biotech was founded in 2017. |
| Where is Krystal Biotech headquartered? | Krystal Biotech is headquartered in United States. |
| How many employees does Krystal Biotech have? | As of today, Krystal Biotech has over 295 employees. |
| Who is the CEO of Krystal Biotech? | Krystal Biotech's CEO is Krish S. Krishnan. |
| Is Krystal Biotech publicly listed? | Yes, Krystal Biotech is a public company listed on Nasdaq. |
| What is the stock symbol of Krystal Biotech? | Krystal Biotech trades under KRYS ticker. |
| When did Krystal Biotech go public? | Krystal Biotech went public in 2017. |
| Who are competitors of Krystal Biotech? | Krystal Biotech main competitors are Kyowa Kirin, Halozyme Therapeutics, ImmunityBio, Cytokinetics. |
| What is the current market cap of Krystal Biotech? | Krystal Biotech's current market cap is $8B. |
| What is the current revenue of Krystal Biotech? | Krystal Biotech's last 12 months revenue is $428M. |
| What is the current revenue growth of Krystal Biotech? | Krystal Biotech revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of Krystal Biotech? | Current revenue multiple of Krystal Biotech is 16.9x. |
| Is Krystal Biotech profitable? | Yes, Krystal Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Krystal Biotech? | Krystal Biotech's last 12 months EBITDA is $182M. |
| What is Krystal Biotech's EBITDA margin? | Krystal Biotech's last 12 months EBITDA margin is 42%. |
| What is the current EV/EBITDA multiple of Krystal Biotech? | Current EBITDA multiple of Krystal Biotech is 40.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.